1. Home
  2. LBPH

LBPH

Longboard Pharmaceuticals Inc.

Logo Longboard Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 2:31pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Founded: 2020 Country:
United States
United States
Employees: N/A City: LA JOLLA
Market Cap: 794.8M IPO Year: 2021
Target Price: $36.14 AVG Volume (30 days): 599.7K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.39 EPS Growth: N/A
52 Week Low/High: $3.60 - $28.15 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: